Data show promising early evidence of anti-tumor activity in patients with relapsed/refractory B cell non-Hodgkin lymphoma BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy ...
Researchers headed by a team at Mass Eye and Ear, Harvard Medical School, reported positive data from a Phase I clinical study evaluating a stem cell treatment known as cultivated autologous limbal ...
The FIRCE-1 trial for firi-cel in LBCL patients was discontinued due to insufficient therapeutic advantage and safety concerns. Firi-cel showed a 77% overall response rate, but only 18% of complete ...
Checkpoint inhibitor therapies can be thought of as the molecular “brake release” for the immune system. These drugs eliminate the protein barriers that block the immune system from recognizing and ...
BNT211 combines two innovative approaches in one regimen with first-in-class potential: an autologous CAR-T cell therapy targeting the oncofetal antigen Claudin-6 (CLDN6) and a CLDN6-encoding CAR-T ...
The Malaghan Institute of Medical Research in collaboration with Wellington Zhaotai Therapies Limited today announced results of its phase 1 dose escalation trial of a new third generation anti-CD19 ...
Scientists have uncovered a new way embryonic cells divide when conventional mechanisms fail. Cell division underpins all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results